[18F]fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer

Eur J Nucl Med. 1989;15(2):61-6. doi: 10.1007/BF00702620.


Seventeen patients with advanced breast cancer were imaged with a specially collimated gamma camera to study tumor uptake of 2-[18F]-fluoro-2-deoxy-D-glucose (FDG) before and during therapy. Fourteen patients (82%) showed increased FDG accumulation in metastatic tumors, 6/8 (75%) of axillary, supra or infraclavicular metastatic lymph nodes were detectable. In one of these cases, FDG imaging was the first method to identify axillary metastasis causing nerve compression. Also, pulmonary and liver metastases could be imaged with FDG; both in two patients. The intra individual variability in uptake was considerable in bone metastases, and some lesions remained FDG negative: 99mTc-DPD was superior in detecting bone disease. Bone metastases of the osteolytic or mixed type were better visualized than sclerotic ones. Ten patients were reimaged later to assess the effect of therapy on FDG uptake. Increased uptake was associated with clinical progression, while unchanged or diminished uptake did not predict the course of disease as reliably. This study indicates that FDG can be used to image breast cancer metastases. FDG may be valuable in monitoring treatment response, but positron emission tomography (PET) would probably be more appropriate than planar imaging for this purpose.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bone Neoplasms / diagnostic imaging
  • Bone Neoplasms / secondary
  • Breast Neoplasms / diagnostic imaging*
  • Breast Neoplasms / therapy
  • Deoxy Sugars*
  • Deoxyglucose* / analogs & derivatives
  • Female
  • Fluorine Radioisotopes*
  • Fluorodeoxyglucose F18
  • Follow-Up Studies
  • Humans
  • Middle Aged
  • Radionuclide Imaging


  • Deoxy Sugars
  • Fluorine Radioisotopes
  • Fluorodeoxyglucose F18
  • Deoxyglucose